Why Match Group Inc (NASDAQ: MTCH) Stock is a Buy

3852 0 0 0 0 2 (0)
Match Group Inc (NASDAQ:MTCH) reported second-quarter revenue of $421 million, up 36% year over year. They have recently moved up on the Hade Platform Top 100 investment grade stock list. Investors will be watching closely when Match Group Inc (NASDAQ:MTCH) reports the financial results of its third quarter after the market closes on Wednesday, Nov. 6.  Even in the wake of the recent market rout, the stock is up more than 50% so far this year. Match Group Inc (NASDAQ:MTCH) is working to keep love alive. 



Looking ahead, although the push and pull of a bull or bear market could certainly alter the outcome, our view is that this stock's positive fundamentals give it good potential for further appreciation. Over the past week, Match Group Inc (NASDAQ:MTCH) investment grade on the Hade Platform has risen steadily, making it a Top 100 stock. Ironically, this stability in overall rating happens during a time when the overall market is falling, and as our investment grades as an average have consistently declined for the last four months, effectively predicting a correction.

With overall investment grades still lower, we suggest holding large sums of cash and being very selective when making investment decisions. According to Match Group stock’s current grade, it might very well be one of those selective opportunities. Why should you trust our ratings? The Hade Platform has proven over the course of three years through the application of DLAs and artificial intelligence that it consistently outperforms Wall Street consensus estimates (63%) and major benchmarks such as the S&P 500 (250%). Access our premium services and start beating the market.

Free users on Hade Platform can build a watchlist of stocks and access investment grades from our database of more than 4,000 securities. Premium members can access the platform to get an instant look at which stocks rate highest for value, growth, dividend, and which have the greatest short-term momentum, thereby allowing members to identify areas of opportunity. Premium services include interest trends, risk analysis, machine learning predictions, Top 100 stocks, MatriX Portfolio and more.


Comments (0)

Recent Updates

  •   
    Jan 19, 2019 9:38 AM

    Sanofi SA (ADR) - Consumer Healthcare Total Revenue

  •   
    Jan 19, 2019 9:38 AM

    Sanofi SA (ADR) - Consumer Helathcare Other of which Gold Bond Revenue

  •   
    Jan 19, 2019 9:38 AM

    Sanofi SA (ADR) - Vaccines Polio/Pertussis/Hib Vaccines (incl. Hexaxim/Hexyon, Pentacel, Pentaxim and Imovax) Revenue

  •   
    Jan 19, 2019 9:38 AM

    Sanofi SA (ADR) - Vaccines Influenza Vaccines (incl. Vaxigrip, Fluzone HD, Fluzone, Flublok) Revenue

  •   
    Jan 19, 2019 9:38 AM

    Sanofi SA (ADR) - Vaccines Meningitis/Pneumo Vaccines (incl. Menactra) Revenue

  •   
    Jan 19, 2019 9:38 AM

    Sanofi SA (ADR) - Vaccines Adult Booster Vaccines (incl. Adacel) Revenue